Both SR9009 and the newer SR9011 have excellent pharmacodynamic properties for REV-ERB activation to increase muscle cell fat oxidation and to turn off the fat storage genes; giving a synergistic effect for overall fat loss.
However due to the inherent nature of the compounds they have poor levels of oral bioavailability.
The SR9009 and SR9011 that we supply has always undergone a micronization process in order to increase this bioavailability, but it is still not on par with when these compounds are administered via injectable or IV pathways.
Hence we are due to release a new Transdermal delivery method where users can perform research studies via transdermal absorption directly through skin.
Our new formulation uses a very similar composition profile as Androgel (testosterone patches), however it will be less viscous for use via direct application as oppose to patches
Units will come with pump applicators each dosing 0.3ml per application (30ml @10mg/ml)
Pricing will also only be slightly higher than the current orally active formulation available for sale on our site.
Register your interest via email to sales@receptorchem.co.uk with subject heading ‘Transdermal’ to be the first to be notified when it is available for sale:
Receptor Chem - Leading Global Distributor of Selective Receptor Modulator Materials
Receptor Chem R&T
Stanmore Business, Science and Innovation Centre
Howard Road
Stanmore, London
HA7 1GB
United Kingdom
+44 7366997493
Questions, issues or concerns? I'd love to help you!